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Objective
Levosimendan, calcium sensitizer, induces contractility
by binding to troponin C without increasing intracellu-
lar calcium concentration. We tested the hypothesis that
levosimendan could produce early and prolonged benefi-
cial effect on left ventricular (LV) systolic function in
patients with normal LV function undergoing off-pump
coronary artery bypass grafting (OPCABG).
Methods
Loading dose of levosimendan at low-dose (12 mcg/kg),
high-dose (24 mcg/kg) or placebo were administered in
thirty-one patients in randomized controlled study.
Bolus thermodilution by pulmonary artery catheter used
for cardiac output (CO) measuring. Numerical data
were described by median. To compare the three
independent groups (low or high-dose levosimendan or
placebo) the Kruskal-Walis test was applied. For com-
paring time points in one group, we tested the differ-
ences in time within each group with the Friedman test.
Results
Significant increase in CO occurred after low-dose
(p = 0.001) and high-dose levosimendan (p < 0.001). CO
was higher in all measurements in patients receiving
low-dose levosimendan versus patients received placebo,
but didn’t rich significance. In patients receiving
low-dose levosimendan, compared with baseline
measurement, CO was higher 20 minutes after infusion
(p = 0.080) and 48 h after surgery (p=0.067). Similar
alteration in CO measurements occurred after high-dose
comparing with low-dose levosimendan. Furthermore,
CO was significantly higher in patients receiving high-
dose levosimendan compared with those receiving
placebo, 20 min after infusion (p = 0.021) and 48 h after
surgery (p = 0.006). Compared with baseline measure-
ment, all values of CO were significantly higher in
patients treated with high-dose levosimendan (p = 0.005
for all).
Conclusion
Levosimendan produces early and prolonged beneficial
effect on left ventricular performance in patients with
preoperative normal LV function undergoing OPCABG
surgery, and this effect is dose dependent.
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